Histology
Adenocarcinoma
CI-CAN-00000403Explore in graph →
2,751 active trials43 approved drugs423 evidence items
Loading cancer entity…
Histology
CI-CAN-00000403Explore in graph →
Clinical trials
9,697 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,318)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06005740 | A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer | active not recruiting | Phase 1 | 70 | TORL Biotherapeutics, LLCINDUSTRY | 2 | Sep 21, 2026 | clinicaltrials |
| NCT06040099 | A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE(EMERALD-Y90) | active not recruiting | Phase 2 | 58 | AstraZenecaINDUSTRY | 1 | Sep 21, 2026 |
| clinicaltrials |
| NCT06176989 | Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors | recruiting | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06929845 | Organoid Models of Hepatocellular Carcinoma | recruiting | N/A | 150 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07200141 | Simultaneous Boost in Neoadjuvant Radiotherapy for Rectal Cancer(SIB-NCRT) | recruiting | Phase 2 | 156 | Peking Union Medical College HospitalOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07629960 | A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations | recruiting | Phase 1 / Phase 2 | 265 | Blueprint Medicines CorporationINDUSTRY | 2 | Sep 21, 2026 | clinicaltrials |
| NCT07639138 | Lenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCC | recruiting | Phase 2 | 32 | Shunda DuOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07645651 | Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer | recruiting | Phase 1 | 15 | University of WashingtonOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07793695 | Oral Zinc Supplementation Combined With Targeted Immunotherapy for Unresectable or Advanced Hepatocellular Carcinoma(ZINC-1LT/IOHCC) | recruiting | Phase 2 | 60 | Anhui Provincial HospitalOTHER_GOV | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07829926 | Lenvatinib Plus Tislelizumab With or Without Gefitinib for Advanced Liver Cancer(LENTIG-HCC) | not yet recruiting | Phase 2 | 120 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 0 | Sep 21, 2026 | clinicaltrials |
| NCT07831330 | Albumin-bound Paclitaxel (II) in Combination With Gemcitabine as First Line Therapy for Metastatic Pancreatic Cancer | not yet recruiting | Phase 2 | 59 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Sep 21, 2026 | clinicaltrials |
| NCT07832006 | Irreversible Electroporation Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma | recruiting | Phase 2 | 30 | Shunda DuOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07832227 | Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial(SIERRA) | not yet recruiting | Phase 2 | 60 | Dana-Farber Cancer InstituteOTHER | 0 | Sep 21, 2026 | clinicaltrials |
| NCT02874885 | Circulating Tumor Cells in Patients With Locally Advanced Rectal Cancer | active not recruiting | — | 341 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT03391869 | Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer | active not recruiting | Phase 3 | 339 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT03776487 | Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer | active not recruiting | Phase 2 | 32 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04090398 | Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones | active not recruiting | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04985565 | Neoadjuvant Dietary Intervention in Intermediate Risk Prostate Cancer | active not recruiting | N/A | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT05048212 | A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases | recruiting | Phase 2 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT05327686 | Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial(SAMURAI) | recruiting | Phase 2 | 240 | NRG OncologyOTHER | 4 | Sep 18, 2026 | clinicaltrials |
| NCT05863052 | Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population | active not recruiting | — | 72 | University of OklahomaOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06900595 | Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer | recruiting | Phase 2 | 48 | National Cancer Institute (NCI)NIH | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06954116 | Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence(CCGLC-017) | recruiting | Phase 2 | 26 | Tongji HospitalOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07340541 | Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies(EVOLVE-BDT) | recruiting | Phase 2 | 700 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07435038 | Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | recruiting | Phase 1 / Phase 2 | 120 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 2 | Sep 18, 2026 | clinicaltrials |
| NCT07450859 | A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) | recruiting | Phase 2 | 39 | BicycleTx LimitedINDUSTRY | 2 | Sep 18, 2026 | clinicaltrials |
| NCT07627191 | GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer | recruiting | Early Phase 1 | 30 | University of ArizonaOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07650240 | Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial(SPARKLE) | recruiting | Phase 2 | 202 | Mayo ClinicOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07688187 | A Study of Theranostic Pair PD-32766D/T in Participants With Carbonic Anhydrase IX Positive Clear Cell Renal Cell Carcinoma | recruiting | Phase 1 | 60 | PeptiDream Inc.INDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07705334 | A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors(Luca-1) | recruiting | Phase 1 | 30 | SHY TherapeuticsINDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07743138 | STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL) | not yet recruiting | Phase 2 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07827053 | Clinical Study of Radiotherapy Combined With Adebrelimab and NALIRIFOX for Conversion Therapy in Locally Advanced Pancreatic Cancer | not yet recruiting | Phase 2 | 36 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 0 | Sep 18, 2026 | clinicaltrials |
| NCT07827807 | PEARL Trial: Partial TACE Enhancing Anti-tumor Response With Lenvatinib in Unresectable HCC(Pearl) | not yet recruiting | Phase 2 | 40 | Chang Gung Memorial HospitalOTHER | 0 | Sep 18, 2026 | clinicaltrials |
| NCT07828236 | PHASE 1 TRIAL OF Lm-LLO-TT AND GEMCITABINE IN UNRESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA | not yet recruiting | Phase 1 | 18 | Loki Therapeutics, Inc.INDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07828249 | Phase I Study Evaluating 161Tb-PSMA Therapy in Adult Patients With Metastatic Clear Cell Renal Cell Carcinoma(PRadR2) | not yet recruiting | Phase 1 | 26 | Centre Leon BerardOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07828652 | Real-world Treatment Outcomes and Safety of Neoadjuvant Pembrolizumab-containing Therapy in Patients With Triple-negative Breast Cancer: Korean Nationwide Multicenter Study (Pembro-Real World) | not yet recruiting | — | 2,000 | Yeon Hee ParkOTHER | 0 | Sep 18, 2026 | clinicaltrials |
| NCT07829185 | Modified FOLFIRINOX and Pentamidine in Advanced and Metastatic Pancreatic Cancer(FALCON) | not yet recruiting | Phase 1 | 30 | University of OklahomaOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT02851784 | Combination Therapy of Microwave Ablation and Cellular Immunotherapy for Hepatocellular Carcinoma | recruiting | Phase 2 / Phase 3 | 80 | Chinese PLA General HospitalOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT04105270 | RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial | recruiting | Phase 2 | 82 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT04152499 | Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)(MK-2870-001) | active not recruiting | Phase 1 / Phase 2 | 1,410 | Klus Pharma Inc.INDUSTRY | 6 | Sep 17, 2026 | clinicaltrials |
| NCT04544111 | PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer | active not recruiting | Phase 2 | 19 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05003752 | Hypo-Combi Trial: Hypofractionated EBRT Plus HDR-BT Boost for Prostate Cancer(Hypo-Combi) | active not recruiting | Phase 1 / Phase 2 | 40 | German Oncology Center, CyprusOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05252585 | A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML) | active not recruiting | Phase 4 | 4 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05616650 | Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor | recruiting | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05665738 | Two-fraction HDR Monotherapy for Localized Prostate Cancer | recruiting | N/A | 17 | University of California, San FranciscoOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06205316 | SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma | active not recruiting | Phase 3 | 118 | Mayo ClinicOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06275737 | POP-UP: a Single-arm, Two-cohort Study: an 8-week Trimodal Pre-habilitation Program for Patients With Pancreatic Ductal Adenocarcinoma and Oesogastric(POP-UP) | recruiting | N/A | 72 | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06916624 | Multicenter Study of 18F-Labeled NY104 for PET/CT Imaging in Renal Cell Carcinoma | recruiting | — | 120 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07020117 | A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors | recruiting | Phase 1 | 150 | Aktis Oncology, Inc.INDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07027436 | Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellular Carcinoma.(DARTS) | recruiting | Phase 3 | 30 | Hamilton Health Sciences CorporationOTHER | 1 | Sep 17, 2026 | clinicaltrials |
Data updated 5 days agoSource updated Sep 21, 2026source: clinicaltrials